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Methoxyflurane Nephropathy
by Richard 1. Mazze*
Investigations of methoxyflurane-induced nephrotoxicity in man have been extensively aided
by the use of an animal model. To be of value the animal model must share similar metabolic
pathways with man and have the same clinical manifestations of the disease process. The Fischer
344ratappearsto meet these criteria.
The predominant factors in theproduction ofmethoxyflurane nephrotoxicity appear to be high
methoxyflurane dosage and serum inorganic fluoride concentration. It is likely that secondary
factors include: (1) a high rate of methoxyflurane metabolism and sepsitivity of the kidney to
inorganic fluoride toxicity; (2) concurrent treatment with other nephrotoxic drugs; (3)
preexisting renal disease; (4) surgery oftheurogenital tract, aorta, orrenal vasculative; (5) repeat
administration of methoxyflurane due to accumulation of inorganic fluoride and, perhaps,
methoxyflurane induction of its own metabolism: and (6) concurrent treatment with enzyme-
inducingdrugs such asphenobarbital.
Specific anesthetic-induced nephrotoxicity was
first reported by Crandell et al. (1) in 13 of 41 pa-
tients anesthetized with methoxyflurane (MOF)
for abdominal surgery. They noted polyuria with
a negative fluid balance, elevation of serum
sodium, serum osmolality, and blood urea nitro-
gen, and fixed urine osmolality close to that of
serum. Patients were unable to concentrate urine
despite fluid deprivation and vasopressin admin-
istration, suggesting that the difficulty was of
renal origin and not due to antidiuretic hormone
(ADH) deficiency. Impairment lasted from 10 to
20 days in most patients, but in three, abnor-
malities persisted for longer than one year. In
1971, Mazze et al. (2,3) reported a controlled, ran-
domized, prospective clinical evaluation of renal
function following methoxyflurane anesthesia.
Abnormalities were found in all cases; patients
exhibited polyuria unresponsive to ADH adminis-
tration, marked weight loss, delayed return of
normal urine concentrating ability, hyperna-
traemia, serum hyperosmolality, elevated BUN
and serum creatinine, increased serum uric acid
and a decrease in uric acid clearance. Nephrotox-
icity was not permanent in any ofthese patients.
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Initial Evidence Relating Methoxyflurane
Metabolism to Nephrotoxicity
It had been suggested by Taves et al. (4) that a
metabolite of methoxyflurane, inorganic fluoride,
was related to its nephrotoxicity. They reported
increased concentrations of inorganic fluoride in
the serum and urine of a patient who had renal
dysfunction following methoxyflurane anesthe-
sia. About the same time, Frascino et al (5) noted
oxalic acid crystals in renal biopsy specimens and
increased urinary oxalic acid excretion in several
patients with renal insufficiency following meth-
oxyflurane anesthesia, Mazze et al. (3) subse-
quently reported increased concentrations of in-
organic fluoride in all patients anesthetized with
methoxyflurane with the highest levels found in
those patients with the greatest impairment of
renal function (Fig. 1). Similarly, patients with
clinically evident nephrotoxicity had mean peak
oxalic acid excretion significantly greater than
patients with laboratory abnormalities only. To
explain the increased excretion of inorganic
fluoride and oxalic acid following methoxyflurane
anesthesia, two complementary metabolic routes
for biotransformation of methoxyflurane were
proposed (Fig. 2). Both inorganic fluoride and ox-
alic acid have nephrotoxic potential with the
formerthe mostlikely cause ofpolyuria.
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FIGURE 1. Mean daily serum inorganic fluoride concentra-
tions. Patients anesthetized with methoxyflurane were
divided into two subgroups, those with laboratory ab-
normalities in renal function and those with laboratory ab-
normalities as well as clinically evident renal dysfunction
(see text). Preoperative inorganic fluoride concentration
was approximately 1 inm/i. in all patients, with no change
noted following halothane anesthesia. F- (pmoles) = inor-
ganic fluoride, ;.noles/l. From Mazze et al. (3), reproduced
withpermission ofAnesthesiology.
Evidence of Methoxyflurane Nephrotoxicity in
an Animal Model
A direct cause-effect relationship of methoxy-
flurane administration and renal dysfunction was
still not conclusively established, in part due to
the absence of nephrotoxicity in animal experi-
ments (6). After studying the renal effects of
methoxyflurane in five rat strains, Mazze et al.
(7) found that Fischer 344 and Buffalo rats
metabolized methoxyflurane to a greater extent
that the other three strains as evidenced by
higher serum and urine inorganic fluoride activi-
ty (Fig. 3). However, only Fischer 344 rats de-
veloped functional (Fig. 4) and pathological evi-
dence of a renal lesion (7). Injection of inorganic
fluoride (NaF)produced a much greater degree of
renal insufficiency in Fischer 344rats than in Buf-
falo rats. It was concluded that there were strain
differences among rats in the rate of metabolism
of methoxyflurane to inorganic fluoride and in its
nephrotoxic effects. A high rate of methoxy-
flurane metabolism and increased susceptibility
to the nephrotoxic effects of inorganic fluoride
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FIGURE 2. Metabolic pathways for the metabolism of
methoxyflurane. In pathway I, methoxyflurane is 0-
demiethylated in the liver, producing 2,2-dichloroacetyl
fluoride and a molecule of hydrogen fluoride. Acetyl fluoride
is further hydrolyzed to dichloracetic acid, liberating
another molecule of hydrogen fluoride. A portion of the
dichloroacetyl acid is excreted in the urine while a second
part is oxidatively dechlorinated to glyoxalic acid. The latter
is enzymatically oxidized to oxalic acid. In pathway II,
Methoxyflurane is enzymatically dechlorinated to 2,2-
difluoromethoxyacetic acid. A portion is excreted in the
urine and a second part 0-demethylated in the liver. Subse-
quent dehydrofluorination and hydrolysis result in oxalic
acid formation. From Mazze et al. (3), reproduced with
persmission ofAnesthesiology.
resulted in polyuric renal insufficiency in Fischer
344rats. Other studies in Fischer 344rats showed
that renal functional and morphological changes
(Fig. 5) were proportional to the dose ofmethoxy-
flurane; polyuria, whether resulting from meth-
oxyflurane anesthesia or from direct injection of
inorganic fluoride, was ADH-resistant (Figs. 6
and 7). (7-9). Subsequently, it was conclusively
established (10) that metabolism of methoxy-
flurane was related to nephrotoxicity; induction
of the mixed function oxidase system in Fischer
344 rats by phenobarbital treatment increased
defluorination and nephrotoxicity (Fig. 8),
whereas enzyme inhibition with SKF 525A re-
sulted in decreased defluorination and an at-
tenuated renallesion (Fig. 9).
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FIGURE 3. Daily serum inorganic fluoride activity (mean ±
S.E.) before anesthesia and after 3 hr of 0.5% methoxy-
flurane anesthesia. Fischer 344 and Bufaalo strain rats had
significantly greater increases than rats of the other three
strains; n = 6: (L-E) Long-Evans rats; (S-D) Sprague-Dawley
rats. From Mazze et al. (7), reproduced with permission
from the Journal of Pharmacology and Experimental
Therapeutics.
The Fischer 344 rat is an excellent model for
studying methoxyflurane nephrotoxicity in man
because (1) both metabolize methoxyflurane to F-
and oxalic acid; (2) both develop polyuria after
MOF which is proportional to serum inorganic F-
level and is pitressin-resistant; (3) both develop
renal function abnormalities (hypernatremia,
elevated BUN, polyuria) after methoxyflurane;
(4)the degree ofnephrotoxicity isproportional to
the dose ofmethoxyflurane.
Etiologyof Nephrotoxicity
Studies in both man (2,11) and animals (7-9)
have shown that the degree of nephrotoxicity
following methoxyflurane anesthesia is propor-
tional to the amount of metabolite resulting from
biotransformation of the drug. The following evi-
dence points to inorganic fluoride rather than ox-
alic acid as the primary nephrotoxic metabolite.
Sodium fluoride injection in Fischer 344 rats re-
sulted in dose-related polyuric renal insufficiency
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FIGURE 4. Daily 24-hr urine volume (mean ± S.E.) before and
after 3 hr of 0.5°h methoxyflurane anesthesia. Significant
postanesthetic increases occurred only in Fischer 344 rats.
From Mazze et al. (7), reproduced with permission from the
Journal ofPharmacology and Experimental Therapeutics.
and pathological abnormalities similar to those
found after methoxyflurane anesthesia (8). Injec-
tion of oxalic acid did not cause these changes
(Fig. 10) (10). In man, acute oxalic acid intoxica-
tion results in classical anuric renal failure;
chronic elevation of oxalic acid excretion is
associated with kidney stone formation (12,13).
Also there is a known potent inhibitory effect of
inorganic fluoride on many enzyme systems, in-
cluding those thought to be involved in sodium
transport (Nat + K+ ATPase) and ADH action
(14).
Thus, it is unlikely that oxalic acid is of im-
portance in the production of the acute lesion of
methoxyflurane nephrotoxicity. However, it is
possible that oxalic acid is a factor in the produc-
tion of the chronic lesion seen in patients with
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FIGURE 5. Electron micrographs of proximal convoluted
tubular cells from the rat. (a) In the unanesthetized control
rat, note the predominance of normally long and thin mito-
chondria (m). Also identified are nucleus (n), basement mem-
brane (bm), and a few scattered dense bodies (db). (b) In a
cell obtained 24 hr following 0.5% methoxyflurane anesthe-
sia for 180 min, mitochondria are swollen and there is some
indentation of the nucleus. (c) In the proximal convoluted
tubular cell obtained 24 hr following 0.75% methoxyflurane
anesthesia for 360 min, there is pronounced mitochondrial
swelling, degeneration and rupture. (mv denotes luminal
microvilli). Electron photomicrographs by courtesy of Dr.
Jon C. Kosek; magnification: (a) 3200X; (b) 2580x; (c) 2900x.
permanent renal impairment. Although the num-
ber of oxalate crystals observed in kidney sec-
tions obtained at renal biopsy or autopsy from pa-
tients with methoxyflurane induced renal failure
have been insufficient to cause significant ob-
struction to urine flow (4,15,16), they could act as
a nidus for imflammation resulting in scarring of
the renaltubules and interstitium.
Site and Mechanism oftheAcute Renal Lesion
Because polyuria following methoxyflurane
anesthesia is ADH-resistant, it was originally
postulated (3) that inorganic fluoride caused
nephrotoxicity by interfering with the action of
ADH in the distal convoluted tubule and collect-
ing duct. However, subsequent animal studies
(7-9) showed that the major pathological lesions
were in the proximal convoluted tubule with
damage ranging from mitochondrial swelling to
necrosis of epithelial cells. Few abnormalities
were noted in the distal nephron. In biopsy and
autopsy specimens, proximal tubular dilatation,
focal necrosis and oxalate crystal deposition
also have been described (4,15,16). Thus it is like-
ly that inorganic fluoride acts by a number of
mechanisms. (1) Interference with iso-osmotic
reabsorption of proximal tubular fluid would
place an excessive load on the more distal
nephron, particularly the ascending limb of the
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FIGURE 6. Pitressin (ADH) administration had no effect on
the increase in 24 hr urine volume following administration
of 0.6% methoxyflurane for 3 hr. SEM=standard error of
mean. From Mazze et al. (8), reproduced with permission of
Anesthesiology.
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loop of Henle, leading to reduced renal medullary
hyperosmolality and decreased reabsorption of
water from the collecting ducts. Large volumes of
dilute urine could then be formed in spite of the
presence of ADH. (2) Inhibition of enzyme sys-
tems necessary for sodium (or chloride) pumping
in the ascending limb of the loop of Henle would
result in decreased renal medullary hyper-
osmolality and polyuric renal insufficiency.
(3) Damage to the collecting ducts would make
them insensitive to ADH. The morphological com-
ponents of the lesions suggested in (2) and (3)
may be to subtle tobe detected by available histo-
logical techniques.
Evidence of Dose-Related Nephrotoxicity in
Man
Although animal studies appeared conclusive,
there was still doubt as to the nephrotoxicity of
methoxyflurane in man (17). In part this was due
to the fact that in the initial study of surgical pa-
tients by Mazze et al. (2,3), methoxyflurane was
not administered in the usual clinical manner, i.e.,
DAYS NaF INJECTION
FIGURE 7. Daily injection of 1.0 ml of O.1M NaF produced a
sustained increase in 24 hr urine volume which was not af-
fected by pitressin (ADH) administration. F- denotes in-
organic fluoride injection. From Mazze et al. (8), reproduced
with permission ofAnesthesiology.
with anesthetic adjuvant drugs. Also, methoxy-
flurane dosage was not precisely defined in that
study. This left unanswered the question of the
relationship of methoxyflurane dosage and renal
dysfunction. Additionally, it was possible that
anesthetic adjuvants such as thiopental and ni-
trous oxide might have protected the kidney
against nephrotoxicity. Therefore a randomized,
prospective study was undertaken in which
methoxyflurane was administered with anes-
thetic adjuvant drugs; methoxyflurane dosage in
each patient was precisely documented and the
renal functional changes that occurred at each
dosage were carefully determined (10). The
results ofthat study conclusively established that
methoxyflurane was a nephrotoxin in man. A
positive correlation was observed among the
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FIGURE 8. Changes in serum inorganic fluoride (F-) concen-
tration and urine volume for the first 2days after anesthesia
(day 15): (C) control group I; (Pb) phenobarbital, 25 mg/kg,
b.i.d., days 11 to 14, group II; (MF) methoxyflurane, 0.25°h
for 1.5 hr, day 15, group III; (Pb-MF) phenobarbital pre-
ceding methoxyflurane, group IV. A = days 7 to 10 minus
days 16 to 17, mean S.E. From Cousins et al. (10),
reproduced with permission of Journal of Pharmacology and
Experimental Therapeutics.
variables which included degree of nephrotoxici-
ty, methoxyflurane dosage and serum inorganic
fluoride concentration. Patients anesthetized
with a methoxyflurane dose of 2.0 MAC-hr or
less* had peak serum inorganic fluoride concen-
trations below 40 pM; this was not associated
with nephrotoxicity (Fig. 11). The threshold of
subclinical toxicity occurred at a dosage of 2.5-3
MAC-hr, corresponding to peak serum inorganic
fluoride levels of 50-80 WM. These patients had
delayed return to maximum preoperative urine
osmolality, unresponsiveness to ADH administra-
tion and elevated serum uric acid concentration.
Mild clinical toxicity occurred at a dosage of 5
MAC-hr (serum inorganic fluoride concentration
90-120 M). In addition to the abnormalities
noted above, serum hyperosmolality, hyper-
natremia, polyuria, and low urine osmolality
were present. Finally, clinical toxicity occurred in
*MAC is the minimum alveolar concentration of anesthetic
necessary to prevent movement in response to surgical incision
in 50% of patients. MAC hours is determined by multiplying
alveolar anesthetic concentration by the duration of adminis-
tration ofanesthetic.
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FIGURE 9. Changes in serum inorganic fluoride (F-) concen-
tration and urine volume for the first 2 days after anesthesia
(day 11): (C) control, group I; (SKF) SKF 525-A, 50mg/kg,
group II; (MF) methoxyflurane, 0.5% for 3 hr, group III;
(SKF-MF) SKF 525-A followed by methoxyflurane, group
IV. = days 7 to 10 minus days 12 to 13, mean + S.E. From
Cousins et al. (10), reproduced with permission of the Jour-
nal ofPhamacology andExperimentalTherapeutics.
all three patients with methoxyflurane dosage
greater than 7 MAC-hr (peak serum inorganic
fluoride levels 80-175 jAM). Abnormalities in
serum and urine variables were even more pro-
nounced than at lower methoxyflurane dosages.
In addition, all three patients were resistant to
ADH (Fig. 12) and had thirst and polyuria which
added difficulty totheir clinical management.
A significant permanent reduction in cre-
atinine clearance was seen only in one patient
who received 9 MAC-hr of methoxyflurane and
required a course of gentamicin for a post-
operative Psuedomonas wound infection. His
creatinine clearance was reduced from 107
ml/min prior to gentamicin treatment to 40
ml/min after 4 days of antibiotic therapy (Fig. 13)
(18). It was subsequently shown in Fischer 344
rats that the adverse renal functional and
pathological effects of gentamicin and
methoxyflurane are additive (19). Other studies
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FIGURE 10. Daily urine volume (mean ± S.E.) before and
after treatment with oxalic acid (OA) and sodium fluoride
(NaF). Dose-related polyuria occurred after NaF injection
but not after OA. Treatment with 444 pmole of oxalic acid
resulted in oliguria. From Mazze et al. (10), reproduced with
permission of the Journal of Pharmacology and Experimen-
tal Therapeutics.
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FIGURE 12. Vasopressin (ADH) infusion tests in four patients
with polyuric renal dysfunction following methoxyflurane
anesthesia. Control infusions are shown for two patients
following halothane anesthesia. Patients anesthetized with
methoxyflurane were unable to decrease urine osmolality in
response to a 1-liter fluid load of50/o dextrose in water or in-
crease urine osmolality after ADH infusion. From Cousins
and Mazze (11), reproduced with permission of the Journal
ofthe American Medical Association.
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FIGURE 11. Peak serum inorganic fluoride concentration (F-)
and degree of nephrotoxicity are shown at increasing doses
of methoxyflurane. Methoxyflurane dose correlated with
both peak serum inorganic fluoride concentration and degree
ofnephrotoxicity. From Cousins and Mazze (11), reproduced
with permission of the Journal of the American Medical
Association.
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FIGURE 13. Preoperative and postoperative uric acid, blood
urea nitrogen (BUN), creatinine clearance (CcJ, creatinine
(Cr), and serum inorganic fluoride (F-). Preoperative values
are means for the three days preceding operation. From
Mazze and Cousins (18), reproduced with permission of the
British Journal ofAnaesthesia.
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117indicated that the toxicity of methoxyflurane is
also increased by concurrent treatment with
tetracycline (20) and other potentially
nephrotoxic drugs.
Finally, a comment about age as a factor in
methoxyflurane nephrotoxicity. Nephrotoxicity
has not been reported in children. Studies in the
Fischer 344 rat animal model suggest this may be
due to greater deposition of inorganic fluoride in
developing bone, thus lowering serum inorganic
fluoride levels (Fig. 14) (21).
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FIGURE 14. Serum inorganic fluoride in rats of various ages
after 2 hr exposure to 0.5% methoxyflurane. Peak values
were directly related to the age ofrats. From Bell et al. (21),
reproduced with permission of the Journal of Pharmacology
and Experimental Therapeutics.
Summary of Factors in the Production of
Methoxyflurane Nephrotoxicity
The predominant factors in the production of
methoxyflurane nephrotoxicity appear to be
mehtoxyflurane dosage and serum inorganic fluo-
ride concentration. It is likely that secondary fac-
tors include: (1) a high rate of methoxyflurane
metabolism and sensitivity of the kidney to in-
organic fluoride toxicity; (2) concurrent treat-
ment with other nephrotoxic drugs; (3) pre-
existing renal disease; (4) surgery of the uro-
genital tract, aorta, or renal vasculative; (5)
repeat administration, of methoxyflurane due to
accumulation of inorganic fluoride and, perhaps,
methoxyflurane induction of its own metabolism;
and (6) concurrent treatment with enzyme induc-
ingdrugs such as phenobarbital.
In summary, investigations of methoxy-
flurane-induced nephrotoxicity in man have been
extensively aided by the use of an animal model.
To be of value the animal model must share
similar metabolic pathways with man and have
the same clinical manifestations of the disease
process. The Fischer 344 rat appears to meet
these criteria.
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